glp 1 analogue GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1-based therapies for diabetes, obesity
Description
31 and 60 million adults live with type 2 diabetes in USA and Europe, respectively
CLINICAL TRIAL EVIDENCE FOR DUAL GLP-1/GLUCAGON RAs AND TRIPLE AGONISTS IN MASH Survodutide Survodutide, a weekly dual GLP-1/GCG agonist, was assessed in a phase 2 dose-finding trial (NCT04771273) including 293 individuals with histologically confirmed MASH and fibrosis stages F1-F3 [46]
New studies back safety of leading diabetes drugs With new diabetes drug classes plagued by toxicity concerns of late, a crop of studies affirming their safety provided welcome relief at the American Diabetes Association (ADA) annual meeting in Boston this week
Certain individuals should not use semaglutide
Fertil Steril, 2017
Muscle Preservation One concern with rapid weight loss is the loss of lean muscle mass along with fat
